Piperacillin

Piperacillin belongs to the penicillin family, with a broad spectrum of action and a bactericidal effect. It acts on the bacterial wall: it binds to the penicillin-binding proteins, the PBPs, the enzymes that assemble peptidoglycan. By blocking the PBPs, it prevents the cross-linking of peptidoglycan and the formation of the septum as the bacterium divides. Deprived of a solid wall, the bacterium eventually ruptures and dies.

Piperacillin is often combined with tazobactam. This second compound does not attack the bacterium directly: it has little affinity for the PBPs. Its role is to inhibit beta-lactamases, enzymes that certain germs produce to break down penicillins. By neutralising these enzymes, tazobactam protects piperacillin and restores its activity against bacteria that would otherwise resist it.

Piperacillin targets bacterial infections that are often severe or acquired in hospital. It is used in intra-abdominal, gynaecological, lower respiratory, urinary and skin infections, as well as in febrile neutropenia, the situation in which immune defences have collapsed and an infection can take hold quickly.

Its broad spectrum explains these uses. It covers many bacteria, including Pseudomonas aeruginosa, a germ known to be difficult, and anaerobes that live without oxygen. The choice of this antibiotic answers a precise target, decided by the medical team according to the site of infection and the suspected germs.

Piperacillin is not absorbed by mouth. It is given by injection, most often intravenously, sometimes intramuscularly. The question of taking it with or between meals therefore does not arise: it is a hospital treatment, set up and monitored by care staff.

The infusion lasts about 30 minutes, and the dose is repeated every 6 to 8 hours depending on the infection and kidney function. This close rhythm reflects a short half-life, on the order of 0.7 to 1.2 hours: the drug leaves the blood quickly, mainly through the urine, where about 68% of piperacillin is found unchanged. Repeating the doses maintains an active concentration against the bacterium.

The most frequent adverse effects involve the digestive tract and the nervous system. In the trials, diarrhoea occurs in 11.3% of patients, constipation in 7.7%, headache in 7.7%, nausea in 6.9% and insomnia in 6.6%. The skin sometimes reacts, with a rash in 4.2% of cases and itching in 3.1%.

A treatment that runs long calls for blood monitoring. Beyond about 21 days, drops in white blood cells have been observed, in the form of leukopenia and neutropenia. A regular blood test follows the blood count and allows the treatment to be adjusted if these values fall.

Piperacillin/tazobactam supplies sodium, on the order of 220 to 440 mg per dose depending on the presentation. This salt load matters in people with heart failure, high blood pressure or kidney failure, for whom sodium is already a daily point of vigilance.

This antibiotic can also lower blood potassium. This hypokalaemia is described in clinical observations, sometimes with metabolic alkalosis, and its incidence has been measured in dedicated studies. The risk rises when potassium stores are already low, or in the presence of diuretics or cytotoxic medicines. In these situations, an electrolyte measurement monitors the potassium level.

Several medicines interact with piperacillin. With anticoagulants, coagulation parameters call for close monitoring. Probenecid lengthens the antibiotic’s half-life by slowing its elimination. Combined with vancomycin, piperacillin raises the risk of kidney injury, which makes it necessary to follow kidney function.

The follow-up therefore brings together several threads: kidney function, the blood count on long treatments, and the electrolytes when potassium is threatened. This treatment is conducted in hospital, and it is not stopped on one’s own initiative: stopping an antibiotic too soon gives the bacterium a chance to come back.